Many elderly breast cancer patients receive palliative local surgery to control potential physical symptoms and avert potential emotional symptoms. Elderly patients with locally advanced breast cancer were identified in the Surveillance, Epidemiology, and End Results cancer database. Mastectomy strongly improved survival within hormone receptor-negative patients, but lumpectomy and mastectomy were not associated with overall survival within hormone receptor-positive patients. Background: Many elderly breast cancer patients might just receive palliative local surgery, especially those with locally advanced breast cancer (LABC). However, palliative tumor removal might lead to perioperative residual tumor growth. In this study, we aimed to determine the survival effect of palliative local surgery without definitive axillary surgery for LABC in elderly patients. Patients and Methods: Patients age 70 years or older diagnosed with T3/4M0 breast cancer, who received no surgery, mastectomy, or lumpectomy without axillary surgery, were identified in the Surveillance, Epidemiology, and End Results cancer database from 1973 to 2014. The overall survival effect of palliative local surgery was determined by using multivariable Cox regression, and propensity score matching was applied to confirm the results. Results: A total of 2616 female breast cancer patients age 70 years or older diagnosed with T3/4M0 (without inflammatory breast cancer) were identified; 1374 received no cancer-directed surgery, 583 received lumpectomy without axillary surgery, and 659 received mastectomy without axillary surgery. Adjusted for potential confounders, both types of palliative local surgeries (lumpectomy: hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.71-1.27; P ¼ .719; mastectomy: HR, 0.88; 95% CI, 0.65-1.17; P ¼ .371) were not associated with overall survival compared with no surgery within hormone receptor-positive patients. However, mastectomy strongly improved survival within hormone receptor-negative patients. Palliative local surgery did not change the patterns of mortality. Conclusion: For elderly patients diagnosed with LABC, not candidates for standard therapies, mastectomy should be recommended as palliative therapy for hormone receptor-negative, but not for hormone receptor-positive patients.
Introduction
Breast cancer remains the most common malignant disease in women. Older women, the fast-growing segment of the population, will represent an increased cohort of breast cancer patients. Approximately 30% of breast cancer cases occur in women older than the age of 70 years. 1, 2 Previous studies have shown that elderly patients with breast cancer are less likely to receive standard curative therapies, but less aggressive therapies, including lower rates of chemotherapy, endocrine therapy, postmastectomy radiation, axillary lymph node dissection, and even local surgery. This might be because of their comorbid conditions and short life expectancy, as well as high stage and lack of medical insurance. 1, [3] [4] [5] [6] [7] [8] What we care about is that a great proportion of elderly patients only received palliative local surgery (mastectomy or lumpectomy) without definitive axillary surgery, 9 including advanced breast cancer patients with fungation, bleeding, and other potential physical symptoms. 10, 11 Moreover, 40% of women older than 70 years and 55% of women older than 80 years are treated with tamoxifen only for their breast cancer, omitting surgery completely in the United Kingdom. 12, 13 Recently, the surgery types and the corresponding survival effects for breast cancer in older women is limited because women older than 70 years have usually been under-represented in most clinical trials. 3, [14] [15] [16] The survival effect of palliative local surgery without axillary surgery for locally advanced breast cancer (LABC) in elderly patients is still unclear. Apart from controlling physical symptoms, local surgery was reported to avert potential emotional symptoms, reduce overall tumor burden, and remove drug-resistant clones, thus might improve survival. 17 Therefore, palliative local surgery seems therapeutic for a proportion of elderly patients diagnosed with LABC. However, there is increasing evidence that tumor removal might lead to perioperative residual tumor growth without systemic therapy, which was associated with tissue trauma, wound formation, inflammation, and immunosuppression. [18] [19] [20] [21] A high probability remains that residual tumor exists after palliative local surgery for LABC, and few of these elderly patients receive systemic therapy.
Figure 1 Flow Diagram of Study Eligibility and Exclusion Criteria
Abbreviations: AJCC ¼ American Joint Commission on Cancer; SEER ¼ Surveillance, Epidemiology, and End Results.
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Palliative Surgery for LABC in Elderly Patients Moreover, breast cancer is a heterogeneous disease, and hormone receptor-positive patients show completely different biological characteristics and clinical outcomes compared with hormone receptor-negative patients. The effects of mastectomy and lumpectomy on hormone receptor-positive and -negative patients might be different in elderly patients.
In the present study, we aimed to determine the survival effect of palliative local surgery (mastectomy and lumpectomy) without definitive axillary surgery for LABC in elderly patients by using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer database. 22 Importantly, the effects of palliative mastectomy or lumpectomy on survival outcomes of hormone receptor-positive or -negative patients were also investigated separately.
Patients and Methods

Data Source
The 
Study Sample
Treatment-Related Variables
Surgery was determined from SEER (no surgery: site-specific surgery [1973-1997 varying with EOD 10-number of lymph nodes examined code 00 since 1988). On the basis of these codes, all included patients did not receive any axillary surgery. Treatment with radiation was determined using SEER claims (procedure codes 1-6). Treatment with chemotherapy was determined from SEER claims (code 1). Adjuvant endocrine therapy was not reported.
Patient and Tumor-Related Variables
Patient characteristics included age at diagnosis, race, year of diagnosis, marital status, and insurance status. Tumor characteristics as reported by SEER included size, Grade, histology, AJCC T3 and T4 disease, AJCC N stage, and laterality. Margin status and lymphevascular space invasion were not reported. For estrogen receptor and progesterone receptor, code 1 and code 2 were recognized as positive and negative, respectively. Hormone receptor-negative was defined as estrogen receptor-and progesterone receptor-negative; and hormone receptor-positive was defined as estrogen receptor-and/or progesterone receptor-positive.
Clinical Outcome
The primary outcome was overall survival (OS) estimated using the KaplaneMeier method. Breast cancer-specific mortality was not included as an outcome because of its questionable validity as reported by SEER.
3,4,23-25
Statistical Analysis
Unadjusted associations of variables among no surgery, lumpectomy, and mastectomy groups were tested using Pearson c 2 . For survival analysis, the KaplaneMeier method was applied for every variable as in univariate analysis; then, variables, with a P value < .05 in the univariate analysis were further involved in the multivariate analysis using a Cox proportional hazards model. The hazard ratio (HR) with 95% confidence interval (CI) was estimated using a Cox regression model for OS. Propensity score matching was applied to confirm the survival effect of palliative local surgery compared with no surgery. The annual mortality rate of these patients was estimated according to life tables and shown in line graph form. All statistical analyses were performed using software (Stata version 11.0; StataCorp, College Station, TX), and a significant difference was concluded for P < .05.
Results
Baseline Characteristics
A total of 2616 female breast cancer patients age 70 years or older diagnosed with T3/4M0 (without inflammatory breast cancer) from 1973 to 2014 were identified ( Table 1 ). The mean age of enrolled patients was 83.1 years (SD, 7.4). Five-and 10-year OS rates were 24.7% and 7.4%. Of these 2616 patients, 1374 did not receive breast cancer-directed surgery, 583 received lumpectomy without definitive axillary surgery, and 659 received mastectomy without axillary surgery. Clinical T4 and node-positive disease was associated with refusal of cancer-directed surgery; more hormone receptor-positive patients Data are presented as n (%). a Includes "unknown," "borderline," and "not 1990þ breast" estrogen receptor and progesterone receptor status.
Palliative Surgery for LABC in Elderly Patients
e250 -Clinical Breast Cancer February 2019 received lumpectomy; chemotherapy use was more preferred among patients in the no surgery group; and more patients in the lumpectomy group received radiation.
Overall Survival After Palliative Local Surgery
The median OS was 23 months (95% CI, 21-26 months) in the no surgery group, 38 months (95% CI, 34-44 months) in the lumpectomy group, and 31 months (95% CI, 29-33 months) in the mastectomy group. Adjusted for potential confounders, lumpectomy was not associated with improved all-cause mortality compared with no surgery (HR, 0.85; 95% CI, 0.65-1.10; P ¼ .222); but mastectomy, with 5-and 10-year OS of 25.4% and 7.2%, respectively, could significantly improve the OS (HR, 0.74; 95% CI, 0.57-0.96; P ¼ .022), compared with 18.1% and 4.1% in patients without surgery. Furthermore, radiation use was significantly associated with reduced risk of death (HR, 0.52; 95% CI, 0.39-0.70; P < .001), whereas chemotherapy use was not (HR, 0.86; 95% CI, 0.63-1.17; P ¼ .344). As expected, hormone receptor-positive status strongly predicted Bold values represent P < .05.
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Clinical Breast Cancer February 2019 -e251 better survival (HR, 0.50; 95% CI, 0.39-0.64; P < .001). Older age at diagnosis and high tumor grade were significantly associated with decreased survival (Table 2) .
Subgroup Analysis According to Hormone Receptor Status
Because of completely different biological characteristics and clinical outcomes, subgroup analysis was performed according to different hormone receptor status (Table 3) . Within hormone receptor-positive patients, advancing age, poorly or undifferentiated tumor, and node stage 2/3 were significantly associated with decreased survival using traditional multivariable Cox regression. Furthermore, radiation use could also strongly improve survival (HR, 0.44; 95% CI, 0.31-0.64; P < .001). However, both types of palliative local surgeries (lumpectomy: HR, 0.95; 95% CI, 0.71-1.27; P ¼ .719; mastectomy: HR, 0.88; 95% CI, 0.65-1.17; P ¼ .371) were not associated with survival compared with no surgery (Figure 2 ). Bold values represent P < .05.
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Different to hormone receptor-positive patients, chemotherapy use could improve the OS (HR, 0.51; 95% CI, 0.30-0.86; P ¼ .011) in hormone receptor-negative patients in multivariable Cox regression, but radiation use had a borderline statistical significance to improve survival (HR, 0.62; 95% CI, 0.36-1.06; P ¼ .080). Interestingly, both types of palliative local surgeries (lumpectomy: HR, 0.50; 95% CI, 0.27-0.94; P ¼ .032; mastectomy: HR, 0.45; 95% CI, 0.26-0.79; P ¼ .006) were associated with improved survival compared with no surgery (Figure 2 ). Other clinical variables, including age at diagnosis, tumor size, node status, tumor grade, clinical T4, and histology, were not associated with OS (Table 3) . To avoid potential selection bias and imbalance of clinical characteristics, propensity score matching analysis was performed to confirm our results. After 1:1 propensity score matching for age, race, T stage, N stage, tumor size, Grade, histology chemotherapy recode, and radiation recode, 144 and 32 pairs of patients were identified in hormone receptor-positive and -negative patients in a comparison of no surgery with lumpectomy, respectively (see Supplemental Table 1 in the online version). In the comparison of no surgery and mastectomy (see Supplemental Table 2 in the online version), 152 and 41 pairs of patients were identified in hormone receptor-positive and -negative groups. Characteristics between these groups were well balanced. The results were consistent with multivariable Cox regression, except for the association of lumpectomy with improved survival in hormone receptor-negative patients (P ¼ .365).
Annual Mortality of Patients Without Radiation and Chemotherapy
To exposit the effect of palliative local surgery on all-cause mortality and natural history of LABC, annual mortalities of enrolled patients without radiation and chemotherapy in different surgery types were calculated (Figure 3) . Within hormone receptorpositive patients, annual mortalities in the 3 groups were similar, and 2 peaks were observed, with a first at the second to third years and a second at the 9th through the14th years. Lumpectomy and mastectomy were not associated with improved OS using multivariable Cox regression (see Supplemental Table 3 in the online version). Within hormone receptor-negative patients, annual mortalities decreased gradually with a peak at the first through third years. In all, lumpectomy (P ¼ .034) and mastectomy (P ¼ .012) significantly improved OS within hormone receptor-negative patients (see Supplemental Table 3 in the online version).
Discussion
To our knowledge, this is the first report about the survival effect of palliative local surgery without axillary surgery in elderly patients diagnosed with LABC. In this population-based cohort study of women with age at 70 years or older diagnosed with T3/4 breast cancer, traditional multivariable Cox regression was first used, and then propensity score matching analysis was applied to confirm the results. Furthermore, patterns of annual all-cause mortality in 3 groups were compared. Our findings help to define appropriate indications for palliative local surgery in elderly patients with LABC to control physical symptoms and avert potential emotional symptoms.
Hormone receptor-positive breast cancer is sensitive to endocrine therapy, and shows better survival than hormone receptor-negative breast cancer. 26 In this study, hormone receptor-positive patients, with 5-and 10-year OS of 23.3% and 6.5%, also showed better survival than hormone receptor-negative patients with 5-and 10-year OS of 13.2% and 2.1%. Similar to the previous study, 4 radiation use, but not chemotherapy, strongly improved survival except for several important clinicopathological features. Interestingly, palliative local surgery did not improve survival in this subtype of patients. The good survival of elderly patients with hormone receptor-positive LABC receiving endocrine therapy might be contributed to the biological characteristics of this type, although the information of endocrine therapy was unknown. On the basis of our results, lumpectomy, but not mastectomy, should be recommended as palliative surgery in elderly patients with hormone receptor-positive LABC with fewer injuries than mastectomy.
In general, hormone receptor-negative breast cancer shows a more aggressive phenotype than hormone receptor-positive cancer. In this subtype of LABC, endocrine therapy is not suitable, and only a small proportion of patients received chemotherapy and radiation in elderly patients with palliative surgery or no surgery in this study. Because of the relatively small sample size, patients who received radiation had a trend toward improved survival, and several important features were not associated with survival in this subtype. However, chemotherapy and palliative surgery were still associated with improved survival using traditional multivariable Cox regression. Mastectomy still strongly improved OS in propensity score matching analysis. Compared with lumpectomy, patients who received mastectomy might have a higher rate of clear margins for this advanced disease, 27 although this is not documented. Total mastectomy is important and should be recommended for these patients without systemic therapy. Previous studies 18, 19 have reported that surgical injury induces changes at the expression level of genes implicated in metastasis, leading to accelerated postoperative residual tumor growth, which might be associated with the imbalance between growth-inducing and growth-inhibiting factors in the tumor microenvironment. 28 In the present study, palliative surgery did not show bad survival effects of these elderly patients with LABC when there was a great chance that residual tumor existed. Different from the previous study, 29 the patterns of mortality in 3 groups were almost the same.
The transient inflammation and immunosuppression status regarding surgical injury might not have adverse effects on OS in these elderly patients. Interestingly, mastectomy strongly improved OS of these elderly patients with hormone receptor-negative LABC, especially for the first year. The results were further confirmed in patients without radiation and chemotherapy. This benefit might be contributed to reduce tumor burden with recovery of immune response in this subtype of patients. 17, 27, 30 Several limitations of this study should be considered when interpreting these results. First, some pathologic information, including Ki-67 status, HER2 status, and lymphovascular invasion, were not available. Furthermore, endocrine therapy and anti-HER2 therapy were not clear. These treatments might not significantly bias the outcomes because administering these treatments to women is on the basis of the pathological assessment, not the types of surgery. 31 Our results still represented the real-world situation in this special portion of patients. Second, because of its retrospective design and limitations of this large cancer database, our results should be confirmed in future cohort studies.
Conclusion
For elderly patients diagnosed with LABC who are not candidates for standard therapies, palliative local surgery is recommended to control physical symptoms and avert potential emotional symptoms.
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For hormone receptor-positive patients, lumpectomy should be considered as palliative therapy because of no survival benefit of mastectomy with more surgical injures. However, mastectomy should be recommended first for hormone receptor-negative patients because of definitive survival benefit. Further studies are urgently needed to define optimal treatment strategies for elderly women with different subtypes of LABC.
Clinical Practice Points
Many elderly breast cancer patients refuse surgery, or receive palliative local surgery. To control potential physical symptoms and avert potential emotional symptoms, palliative local surgery is needed for elderly patients diagnosed with LABC. However, tumor removal might lead to perioperative residual tumor growth. The effects of palliative mastectomy or lumpectomy without axillary surgery on survival outcomes of hormone receptor-positive or -negative patients were not known. In this study, using the SEER cancer database, lumpectomy and mastectomy were not associated with overall survival compared with no surgery within hormone receptor-positive patients. However, mastectomy strongly improved survival within hormone receptor-negative patients. Therefore, for elderly patients diagnosed with LABC, who are not candidates for standard therapies, mastectomy should be recommended as palliative therapy for hormone receptor-negative patients, and lumpectomy for hormone receptor-positive patients.
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